Target Name: SEMA3F
NCBI ID: G6405
Review Report on SEMA3F Target / Biomarker Content of Review Report on SEMA3F Target / Biomarker
SEMA3F
Other Name(s): Sema III/F | Semaphorin 3F, transcript variant 1 | Semaphorin IV | SEMA-IV | sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F | SEMA4 | Semaphorin-3F (isoform 1) | Semaphorin-3F | SEMAK | semaphorin 3F | Semaphorin III/F | SEM3F_HUMAN | Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3F | semaphorin III/F | Sema IV | sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3F | SEMA3F variant 1 | semaphorin IV

SEMA3F: A Potential Drug Target for Various Diseases

SEMA3F, or semaphorin-3F, is a protein that is expressed in various tissues throughout the body, including the nervous system, endothelial cells, and epithelial cells. It is a member of the semaphorin family of transmembrane proteins, which are known for their ability to regulate cell-cell and cell-tissue interactions and play a role in various physiological processes, including embryonic development, tissue repair, and signaling.

SEMA3F has been identified as a potential drug target due to its involvement in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has also been implicated in several diseases, including heart failure, ischemia, and neuroinflammation.

One of the key functions of SEMA3F is its role in the regulation of cell-cell interactions and cell-tissue interactions. It is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues and is critical for various physiological processes, including embryonic development and tissue repair. SEMA3F is also involved in the regulation of cell proliferation and has been shown to play a role in the development and progression of several types of cancer.

In addition to its role in cell-cell and cell-tissue interactions, SEMA3F is also involved in the regulation of inflammation and has been implicated in the development and progression of several types of inflammatory diseases, including neurodegenerative diseases and autoimmune disorders. Its expression has been shown to be involved in the regulation of inflammation-related signaling pathways, including the production of pro-inflammatory cytokines and the activation of innate immune pathways.

SEMA3F has also been shown to play a role in the regulation of cellular signaling pathways that are involved in various physiological processes, including embryonic development, tissue repair, and signaling. It is involved in the regulation of processes such as cell adhesion, migration, and the formation of tissues and organs during development.

In conclusion, SEMA3F is a protein that is involved in a variety of cellular processes that are important for various physiological functions. Its expression has been implicated in the development and progression of several types of cancer, neurodegenerative diseases, and autoimmune disorders. As a result, SEMA3F is a potential drug target that could be used to treat a variety of diseases.

Protein Name: Semaphorin 3F

Functions: May play a role in cell motility and cell adhesion

The "SEMA3F Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEMA3F comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

SEMA3G | SEMA4A | SEMA4B | SEMA4C | SEMA4D | SEMA4F | SEMA4G | SEMA5A | SEMA5A-AS1 | SEMA5B | SEMA6A | SEMA6A-AS1 | SEMA6A-AS2 | SEMA6B | SEMA6C | SEMA6D | SEMA7A | Semenogelin | SEMG1 | SEMG2 | SENCR | SENP1 | SENP2 | SENP3 | SENP3-associated complex | SENP3-EIF4A1 | SENP5 | SENP6 | SENP7 | SENP8 | SEPHS1 | SEPHS1P4 | SEPHS1P6 | SEPHS2 | SEPSECS | SEPSECS-AS1 | SEPT5-GP1BB | SEPTIN1 | SEPTIN10 | SEPTIN11 | SEPTIN12 | SEPTIN14 | SEPTIN2 | SEPTIN3 | SEPTIN4 | SEPTIN4-AS1 | SEPTIN5 | SEPTIN6 | SEPTIN7 | SEPTIN7-DT | SEPTIN7P11 | SEPTIN7P14 | SEPTIN7P2 | SEPTIN7P6 | SEPTIN7P9 | SEPTIN8 | SEPTIN9 | SERAC1 | SERBP1 | SERBP1P3 | SERF1A | SERF1B | SERF2 | SERF2-C15ORF63 | SERGEF | SERHL | SERINC1 | SERINC2 | SERINC3 | SERINC4 | SERINC5 | Serine (or cysteine) proteinase inhibitor clade F | Serine palmitoyltransferase | Serine protease | Serine protease inhibitor | Serine-aspartate repeat-containing protein I-like | SERP1 | SERP2 | SERPINA1 | SERPINA10 | SERPINA11 | SERPINA12 | SERPINA13P | SERPINA2 | SERPINA3 | SERPINA4 | SERPINA5 | SERPINA6 | SERPINA7 | SERPINA9 | SERPINB1 | SERPINB10 | SERPINB11 | SERPINB12 | SERPINB13 | SERPINB2 | SERPINB3 | SERPINB4 | SERPINB5 | SERPINB6